Reference
Delea TE, et al. Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. PharmacoEconomics : 9 Dec 2014. Available from: URL: http://doi.org/10.1007/s40273-014-0241-z
Rights and permissions
About this article
Cite this article
Dabrafenib "unlikely to be cost effective" in Canada. PharmacoEcon Outcomes News 718, 19 (2014). https://doi.org/10.1007/s40274-014-1784-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1784-0